Skip to main content
SpringerLink
Log in

Role of AP-2 in Tumor Growth and Metastasis of Human Melanoma

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

We previously demonstrated that expression of the cell surface adhesion molecule MCAM/MUC18 correlates directly with the metastatic potential of human melanoma cells. In addition, the progression of human melanoma towards the metastatic phenotype is associated with loss of expression of the tyrosine-kinase receptor c-KIT. This review summarizes our recent data demonstrating that the expression of both genes is regulated by the AP-2 transcription factor. Moreover, we have observed a loss of AP-2 expression in metastatic melanoma cells. Re-expression of AP-2 in the highly metastatic A375SM cells decreased their tumorigenicity and inhibited their metastatic potential in nude mice. MCAM/MUC18 mRNA and protein expression was significantly downregulated while c-kit expression was upregulated in the AP-2 transfected cells. Since AP-2 also regulates other genes that are involved in the progression of human melanoma such as E-cadherin, MMP-2, p21WAF-1, HER-2, BCL-2, and insulin like growth factor receptor-1, we propose that loss of AP-2 is a crucial event in the development of malignant melanoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kopf AW, Slopek TG, Slade J, Marghoob AA, Bart RS: Techniques of cutaneous examination for the detection of skin cancer. Cancer 75: 684-690, 1995

    Google Scholar 

  2. Fidler IJ: Critical factors in the biology of human cancer metastasis. Cancer Res 50: 6130-6138, 1990

    Google Scholar 

  3. Lassam N, Bickford S: Loss of c-KIT expression in cultured melanoma cells. Oncogene 7: 51-56, 1992

    Google Scholar 

  4. Natali PG, Nicotra MR, Winkler AB, Cavaliere R, Bigotti A, Ullrich A: Progression of human cutaneous melanoma is associated with loss of expression of c-KIT protooncogene receptor. Int J Cancer 52: 197-201, 1992

    Google Scholar 

  5. Zakut R, Perlis R, Eliyahu S, Yarden Y, Givol D, Lyman SD, Halaban R: KIT ligand (mast cell growth factor) inhibits the growth of KIT-expressing melanoma cells. Oncogene 8: 2221-2229, 1993

    Google Scholar 

  6. Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Mumenitus S, Dull TJ, Chen E, Schlessinger J, Francke U, Ullrich A: A human proto-oncogene c-KIT: a new cell surface receptor tyro sine kinase for an unidentified ligand. EMBO J 6: 3342-3351, 1987

    Google Scholar 

  7. Chabot B, Stephenson DA, Chapman VM, Besmer P, Bernstein A: The protooncogene c-KIT encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 335: 88-89, 1988

    Google Scholar 

  8. Geisler EN, Ryan MA, Housman DE: The dominant white spotting (W) locus of the mouse encodes the c-KIT protooncogene. Cell 55, 185-192, 1988

    Google Scholar 

  9. Zsebo KM, Williams DA, Geissler EN, Broudy VC, Martin FH, Atkins HL, Hsu RY, Birkett NC, Okino KH, Murdock DC, Jacobson FW, Langley KE, Smith KA, Takeishi T, Cattanach BM, Galli SJ, Snuggs S: Stem cell factor is encoded at the SL locus of the mouse and is the ligand for the c-KIT tyrosine kinase receptor. Cell 63: 213-224, 1990

    Google Scholar 

  10. Nocka K, Majumder S, Chabot B, Ray P, Cervone M, Bernstein A, Besmer P: Expression of the c-KIT gene products in known cellular targets of W mutations in normal and W mutant mice: Evidence for impaired c-KIT kinase in mutant mice. Genes Dev 3: 816-826, 1989

    Google Scholar 

  11. Brannan CI, Lyman SD, Williams DE, Eisenman J, Anderson D, Cosman D, Bedell MA, Jenkins NA, Coopeland NG: Steel-Dickie mutation encodes a c-KIT ligand lacking transmembrane and cytoplasmic domains. Proc Natl Acad Sci USA 88: 4671-4674, 1991

    Google Scholar 

  12. Nishikawa S, Kusakabe M, Yoshingaga K, Ogawa M, Hayashi SI, Kunisada T, Era T, Sakakura T, Nishikawa SI.: In vitro manipulation of coat color formation by a monoclonal anti-c-KIT antibody: two distinct waves of c-KIT dependency during melanocyte development. EMBO J 10: 2111-2118, 1991

    Google Scholar 

  13. Giebel LB, Spritz RA: Mutation of the KIT (mast/stem cell growth factor receptor) proto-oncogene in human piebaldism. Proc Natl Acad Sci USA: 88: 8696-8699, 1991

    Google Scholar 

  14. Fleischman RA, Saltman KL, Stastny V, Zneimer S: Deletion of the c-KIT protooncogene in the human development defect piebald trait. Proc Natl Acad Sci USA 88: 10885-10889, 1991

    Google Scholar 

  15. Huang S, Luca M, Gutman M, McConkey DJ, Langley KE, Lyman SD, Bar-Eli M: Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor induced apoptosis and inhibits their tumorigenic and metastatic potential. Oncogene 13: 2339-2347, 1996

    Google Scholar 

  16. Lehmann JM, Holzmann B, Breitbart EW, Schmiegelow P, Riethmuller G, Johnson JP: Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 76,000. Cancer Res 47: 841-845, 1987

    Google Scholar 

  17. Holzmann B, Brocker EB, Lehmann JM, Rutter DJ, Sorg C, Riethmuller G, Johnson JP: Tumor progression in human melanoma: five stages defined by their antigenic phenotypes. Int J Cancer 39: 466-471, 1987

    Google Scholar 

  18. Breslow A: Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 172: 902-908, 1970

    Google Scholar 

  19. Luca M, Hunt B, Bucana CD, Johnson JP, Fidler IJ, Bar-Eli M: Direct correlation between MUC18 expression and metastatic potential of human melanoma cells. Melanoma Res 3: 35-41, 1993

    Google Scholar 

  20. Bani MR, Rak J, Adachi D, Wiltshire R, Trent JM, Kerbel RS, Ben-David Y: Multiple features of advanced melanoma recapitulated in tumorigenic variants of early state (radial growth phase) human melonoma cell lines: evidence for a dominant phenotype. Cancer Res 56: 3075-3086, 1996

    Google Scholar 

  21. Xie S, Huang S, Luca M, Gutman M, Reich R, Johnson JP, Bar-Eli M: Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis. Cancer Res 57: 2295-2303, 1997

    Google Scholar 

  22. Lehmann JM, Riethmuller G, Johnson JP: MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Sci USA 89: 9891-9895, 1989

    Google Scholar 

  23. Sers C, Kirsch K, Rothbacher U, Riethmuller G, Johnson JP: Genomic organization of the melanoma-associated glycoprotein MUC18: implications for the evolution of the immunoglobulin domains. Proc Natl Acad Sci USA 90: 8514-8518, 1993

    Google Scholar 

  24. Shih IM, Elder DE, Speicher D, Johnson JP, Herlyn M: Isolation and functional characterization of the A32 melanoma-associated antigen. Cancer Res 54: 2514-2520, 1995

    Google Scholar 

  25. Johnson JP, Bar-Eli M, Jansen B, Markhuf E: Melanoma progression-associated glycoprotein MUC18/MCAM mediates homotypic cell adhesion through interaction with a heterophilic ligand. Int J Cancer 73: 769-774, 1997

    Google Scholar 

  26. Bar-Eli M: Molecular mechanisms of melanoma metastasis. J Cell Physiol 173: 275-278, 1997

    Google Scholar 

  27. Williams T, Admon A, Luscher B, Tjian R: Cloning and expression of AP-2, a cell-type-specific transcription factor that activates inducible enhancer elements. Genes Dev 2: 1557-1569, 1988

    Google Scholar 

  28. Gaynor RB, Muchardt C, Xia YR, Klisak I, Mohandas T, Sparkes RS, Lusis AJ: Localization of the gene for the DNA-binding protein AP-2 to human chromosome 6p 22.3 pter. Genomics 10: 1100-1102, 1991

    Google Scholar 

  29. Mitchell PJ, Timmons PM, Hebert JM, Rigby PW, Tjian R: Transcription factor AP-2 is expressed in neural crest cell lineages during mouse embryogenesis. Genes Dev 5: 105-119, 1991

    Google Scholar 

  30. Mitchell PJ, Wang C, Tjian R: Positive and negative regulation of transcription in vitro: Enhancer-binding protein AP-2 is inhibited by SV40 antigen. Cell 50: 847-861, 1987

    Google Scholar 

  31. Williams T, Tjian R: Characterization of a dimerization motif in AP-2 and its function in heterologous DNA-binding proteins. Science 251: 1067-1071, 1991

    Google Scholar 

  32. Buettner R, Kannan P, Imhof A, Bauer R, Yim SO, Glackshuber R, van Dyke MW, Tainsky MA: An alternatively spliced mRNA from the AP-2 gene encodes a negative regulator of transcriptional activation of AP-2. Mol Cell Biol 13: 4174-4185, 1993

    Google Scholar 

  33. Luscher B, Mitchell PJ, Williams T, Tjian R: Regulation of transcriptional factor AP-2 by the morphogen retinoic acid and by second messengers. Genes Dev 3: 1507-1517, 1989

    Google Scholar 

  34. Schorle H, Meier P, Buchert M, Jaenisch R, Mitchell PJ: Transcription factor AP-2 essential for cranial closure and craniofacial development. Nature 381: 235-238, 1996

    Google Scholar 

  35. Zhang J, Hagopian-Donaldson S, Serbedzija G, Elsemore J, Plehn-Dujowich D, McMahon AP, Flavell RA, Williams T: Neural tube, skeletal and body wall defects in mice lacking transcription factor AP-2. Nature 381: 238-241

  36. Karjalainen JM, Kellokoski JK, Eskelinen MJ, Alhava EM, Kosma V-M: Downregulation of transcription factor AP-2 predicts poor survival in stage I cutaneous malignant melanoma. J Clin Oncol 16: 3584-3591,1998

    Google Scholar 

  37. Yamamoto K, Tojo A, Aoki N, Shibuya A: Characterization of the promoter region of the human c-KIT protooncogene. Jpn J Cancer Res 84: 1136-1144, 1993

    Google Scholar 

  38. Orr-Urtreger A, Avivi A, Zimmer Y, Givol D, Yarden Y, Lonai P: Developmental expression of c-KIT, a proto-oncogene encoded by the W locus. Development 109: 911-923, 1990

    Google Scholar 

  39. Huang S, Jean D, Luca M, Tainsky M, Bar-Eli M: Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis. EMBO J 17: 4358-4369, 1998

    Google Scholar 

  40. Luca M, Xie S, Gutman M, Huang S, Bar-Eli M: Abnormalities in the CDKN2 (p16INK4/mts-l) gene in human melanoma cells: relevance to tumor growth and metastasis. Oncogene 11: 1399-1402, 1995

    Google Scholar 

  41. Jean D, Gershenwald JE, Huang S, Luca M, Hudson MJ, Tainsky AM, Bar-Eli M: Loss of AP-2 results in upregulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melanoma cells. J Biol Chem 273: 16501-16508, 1988

    Google Scholar 

  42. Luca M, Huang S, Gershenwald JE, Singh RK, Reich R, Bar-Eli M: Expression of IL-8 by human melanoma cells upregulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol 151: 1105-1113, 1997

    Google Scholar 

  43. Singh RK, Gutman M, Reich R, Bar-Eli: Ultraviolet B irradiation promotes tumorigenic and metastatic properties in primary cutaneous melanoma via induction of interleukin 8. Cancer Res 55: 3669-3674, 1995

    Google Scholar 

  44. Cowley GP, Smith ME: Cadherin expression in melanocytic naevi and malignant melanomas. Am J Pathol 179: 183-187, 1996

    Google Scholar 

  45. Jiang H, Lin J, Su ZZ, Herlyn M, Kerbel RS, Weissman BE, Welch DR, Fisher PB: The melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation and progression in human melanoma cells. Oncogene 10: 1855-1864, 1995

    Google Scholar 

  46. Vidal MJ, Loganzo F Jr, de Oliveira AR, Hayward NK, Albino AP: Mutations and defective expression of the WAF-1 p21 tumor-suppressor gene in malignant melanomas. Melanoma Res 5: 243-250, 1995

    Google Scholar 

  47. Natali PG, Nicotra MR, Digiesi G, Cavaliere R, Bigotti A, Trizio D, Segatto O: Expression of gp 185 HER-2 in human cutaneous melanoma: implications for experimental immunotherapeutics. Int J Cancer 56: 341-346, 1994

    Google Scholar 

  48. Descheemaeker KA, Syns S, Nelles L, Auwerx J, Ny T, Collen D: Interaction of AP-1-like, AP-2-like and SP-1-like proteins with two distinct sites in the upstream regulatory region of the plasminogen activator inhibitor-1 gene mediates the phorbol 12-myristate 13-acetate response. J Biol Chem 267: 15086-15091, 1992

    Google Scholar 

  49. van den Oord JJ, Vandeghinste N, De Ley M, De Wolf-Peeters C: Bcl-2 expression in human melanocytes and melanocytic tumors. Am J Pathol 145: 294-300, 1994

    Google Scholar 

  50. Bosher JM, Williams T, Hurst HC: The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma. Proc Natl Acad Sci USA 92: 744-747, 1995

    Google Scholar 

  51. Zeng YX, Somasundaran K, El-Deiry WS: AP-2 inhibits cancer cell growth and activates p21WAF/CIP1 expression. Nature Genet 15: 78-82, 1997

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

    Menashe Bar-Eli

Authors
  1. Menashe Bar-Eli
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bar-Eli, M. Role of AP-2 in Tumor Growth and Metastasis of Human Melanoma. Cancer Metastasis Rev 18, 377–385 (1999). https://doi.org/10.1023/A:1006377309524

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006377309524

Search

Navigation